PAH
Merck Makes Strong Case for Winrevair in Earlier-Stage Pulmonary Arterial Hypertension (PAH) Patients After Positive Phase 3 HYPERION Results
Winrevair; Merck; HYPERION study; PAH; sotatercept; clinical worsening; early disease; activin signaling; FDA approval; Phase 3 trial
Insmed’s ‘Unprecedented’ Phase 2 PAH Results Propel Stock and Next-Phase Plans
Insmed; PAH; TPIP; Phase 2b; clinical trial; treprostinil palmitil inhalation powder; stock surge; pulmonary arterial hypertension; Phase 3 trial; biotech
Insmed’s TPIP PAH Therapy Advances to Phase III Following Positive Phase 2b Results
Insmed; TPIP; treprostinil palmitil inhalation powder; pulmonary arterial hypertension; PAH; Phase 2b trial; Phase III trial; clinical trial results; FDA engagement
Keros Therapeutics Halts Pulmonary Hypertension Drug After Safety Issues, Cuts 45% of Workforce
Keros Therapeutics; cibotercept; pulmonary arterial hypertension; PAH; layoffs; pericardial effusion; drug development halt; cost savings; biotech sector
Merck’s Winrevair Slashes Morbidity and Mortality Risk in Pulmonary Arterial Hypertension
Winrevair, pulmonary arterial hypertension (PAH), Phase III ZENITH trial, morbidity, mortality, Merck
Keros Therapeutics Faces Major Setback as PAH Trial Dosing Suspended Over Safety Concerns
Keros Therapeutics, PAH trial, dosing suspension, safety concerns, pulmonary arterial hypertension, cibotercept (KER-012), Phase II TROPOS trial
Merck’s Winrevair Demonstrates Significant Mortality Benefit in Pulmonary Arterial Hypertension Patients
Winrevair, Pulmonary Arterial Hypertension (PAH), Mortality Benefit, Sotatercept, Merck & Co.
Merck Advances with Winrevair: Positive Phase III Results in Severe Pulmonary Arterial Hypertension (PAH) Study
Merck, Winrevair, PAH, Phase III, ZENITH study, pulmonary arterial hypertension, cardiovascular drug, morbidity, mortality